Gibson Dunn & Crutcher LLP is advising 89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, on its up to $3.5 billion sale to Roche Holdings, Inc.
The corporate team is led by Partners Branden Berns, Ryan Murr, and Evan D’Amico and includes Partners Karen Spindler, Melanie Neary, and George Sampas and Associates Jonathan Sapp, Ayushi Sutaria, Lauren Navarro, and Risa Nakagawa.
Partner Sean Feller and of Counsel Alli Balick are advising on employee compensation and benefits matters; Partner Pamela Lawrence Endreny and Associate Bree Gong are advising on tax matters; and Michael J. Perry is advising on U.S. and foreign antitrust and competition matters.
Sidley Austin LLP advised Roche Holdings, Inc.
The deal reporting on this platform is based on the information received from law firms, and therefore, some details may be missing/incomplete. If your firm has not been credited for this deal, write to us at chanchal.makhija@thegreymatter.co.in mentioning your firm’s name, lawyers involved (including designation) and client represented.
